XML 72 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Foreign Currency Exchange Contracts and Hedging (Tables)
12 Months Ended
Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments
As of March 31, 2018, the Company had the following foreign currency exchange rate forward contracts:
 
Designated Derivative Contracts
 
Non-Designated Derivative Contracts
 
Total
Notional value
$
126,332

 
$
4,802

 
$
131,134

Fair value recorded in other current assets
950

 

 
950

Fair value recorded in other accrued expenses
(143
)
 
(10
)
 
(153
)


As of March 31, 2017, the Company had the following foreign currency exchange rate forward contracts:
 
Designated Derivative Contracts
 
Non-Designated Derivative Contracts
 
Total
Notional value
$
100,000

 
$

 
$
100,000

Fair value recorded in other current assets
1,365

 

 
1,365

Schedule of location and amount of gains and losses related to derivatives not designated as hedging instruments reported in consolidated financial statements
The following table summarizes the effect of Non-Designated Derivative Contracts:
 
Years Ended March 31,
 
2018
 
2017
 
2016
Location of amount recognized in income on derivative instruments
SG&A expenses
Amount of (loss) gain recognized in income on derivative instruments
$(2,574)
 
$2,202
 
$(1,532)


Schedule of location and amount of gains and losses related to derivatives designated as hedging instruments reported in consolidated financial statements
The following table summarizes the effect of Designated Derivative Contracts:
 
Years Ended March 31,
 
2018
 
2017
 
2016
Location of amount reclassified from accumulated other comprehensive loss into income (effective portion)
Net sales
Amount of (loss) gain recognized in other comprehensive income (loss) on derivative instruments (effective portion)
$(9,593)
 
$8,208
 
$(850)
Amount of (loss) gain reclassified from accumulated other comprehensive loss into income (effective portion)
$(8,541)
 
$7,082
 
$(1,592)
Location of amount excluded from effectiveness testing
SG&A expenses
Amount of gain excluded from effectiveness testing
$1,376
 
$534
 
$207